drugset / Trial / NCT03919175
Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to assess Umbralisib and Rituximab as a first line therapy for Follicular Lymphoma or Marginal Zone Lymphoma.
Timeline
- Start
- 2019-09-01
- Primary completion
- 2024-05-05
- Completion
- 2024-05-05
Outcome
Outcome not reported
Stopped (Enrollment): “Umbralisib development terminated; closed to accrual 8/29/2022”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 1400 mg | Intravenous |
| Subject | Umbralisib | Small molecule | 800 mg | Oral |